Previous close | 10.10 |
Open | 10.13 |
Bid | 10.19 x 100 |
Ask | 10.22 x 100 |
Day's range | 10.02 - 10.29 |
52-week range | 7.72 - 27.48 |
Volume | |
Avg. volume | 1,099,996 |
Market cap | 1.379B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.59 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 32.29 |
SAN FRANCISCO, March 05, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the
Q4 2023 Vir Biotechnology Inc Earnings Call
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript February 22, 2024 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.86, expectations were $-1.14. Vir Biotechnology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello. Welcome to Vir […]